Miltenyi Biotec is one of the world’s leading providers of products and services for biomedical research and cell and gene therapy. The company is committed to enabling the delivery of new treatment options to patients with unmet medical need.
Miltenyi Biotec’s portfolio of innovative solutions and enabling technologies has set new standards in the industry. The company has more than 1,800 employees in 25 countries and its products have been used in more than 50,000 cell therapy procedures. Our state-of-the-art technologies and products provide integrated workflows for research and clinical applications, covering sample preparation, cell separation, cell activation, cell transduction and electroporation, cell culture, formulation, and cell analysis. We develop generic and customized cell processing protocols on our GMP-compliant cell processing platform, the CliniMACS Prodigy®, to enable automated manufacture of complex cellular products such as CAR T cells, TCR-transduced T cells, and gene-modified stem cells.
At its affiliate Lentigen Technology Inc., Miltenyi Biotec designs and develops customized lentiviral vectors, and manufactures cGMP lentiviral vectors for clinical use. Lentigen’s viral vector products allow seamless integration into Miltenyi Biotec’s cell and gene therapy workflow solutions.